Covid-19 Cepiva

Uporabnik AndrejEnej je napisal:

Aja, torej imaš izbiro, kakšen zrak boš dihal in kakšno hrano boš jedel? Imaš, če si doma nekje v hribih in če ješ svojo predelano hrano.

Klikni za razširitev

Sicer pa, tudi cepljenje je lastna odločitev. Zakaj prisila?

Klikni za razširitev

Uporabnik Matey je napisal:

To je že v igri, čip dobiš istočasno s cepivom in med drugim tudi zaznava/sporoča koliko od treh let življenja po cepljenju ti še ostane:

The world's smallest single-chip system with a total volume of less than 0.1 mm3 to measure temperature inside the body and much more

Klikni za razširitev

Uporabnik Mare2 je napisal:

Aha, zaradi tega čipa na vbodenem delu kake tri dni čutiš srbenje.

Klikni za razširitev

Uporabnik Fly je napisal:

Evo cez 20 min imam cepljenje. Zdele grem. A morm pol kej pazit u štacunah da nisem preblizu pulta da se čip ne razmagneti?

Klikni za razširitev

Uporabnik Fly je napisal:

Evo cez 20 min imam cepljenje. Zdele grem. A morm pol kej pazit u štacunah da nisem preblizu pulta da se čip ne razmagneti?

Klikni za razširitev

Real World COVID Vaccine effectiveness (Lancet), Indoor Occupancy Limitations Questioned (MIT) Data.​

COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room​

COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room

Approximately 96 COVID-19 vaccines are at various stages of clinical development.1 At present, we have the interim results of four studies published in scientific journals (on the Pfizer–BioNTech BNT162b2 mRNA vaccine,2 the Moderna–US National Institutes of Health [NIH] mRNA-1273 vaccine,3 the...

www.thelancet.com

Vaccine efficacy is generally reported as a relative risk reduction (RRR). It uses the relative risk (RR)—ie, the ratio of attack rates with and without a vaccine—which is expressed as 1–RR. Ranking by reported efficacy gives relative risk reductions of 95% for the Pfizer–BioNTech, 94% for the Moderna–NIH, 90% for the Gamaleya, 67% for the J&J, and 67% for the AstraZeneca–Oxford vaccines. However, RRR should be seen against the background risk of being infected and becoming ill with COVID-19, which varies between populations and over time. Although the RRR considers only participants who could benefit from the vaccine, the absolute risk reduction (ARR), which is the difference between attack rates with and without a vaccine, considers the whole population. ARRs tend to be ignored because they give a much less impressive effect size than RRRs: 1·3% for the AstraZeneca–Oxford, 1·2% for the Moderna–NIH, 1·2% for the J&J, 0·93% for the Gamaleya, and 0·84% for the Pfizer–BioNTech vaccines.

Klikni za razširitev

Although the design and methodology are radically different from the randomised trial,2
Dagan and colleagues11 report an RRR of 94%, which is essentially the same as the RRR of the phase 3 trial (95%) but with an ARR of 0·46%, which translates into an NNV of 217 (when the ARR was 0·84% and the NNV was 119 in the phase 3 trial). This means in a real-life setting, 1·8 times more subjects might need to be vaccinated to prevent one more case of COVID-19 than predicted in the corresponding clinical trial.

Klikni za razširitev

Uporabnik Fly je napisal:

Evo cez 20 min imam cepljenje. Zdele grem. A morm pol kej pazit u štacunah da nisem preblizu pulta da se čip ne razmagneti?

Klikni za razširitev